Tom Plitz (L) and Arthur Roach, Chord Therapeutics CEO and founder
December 20, 2021 10:56 AM EST
Deals

Mer­ck KGaA snatch­es up Gene­va biotech as re­pur­posed chemother­a­py mis­sion strikes a 'Chord'

Nicole DeFeudis

Editor

About a year af­ter Gene­va-based Chord Ther­a­peu­tics emerged from stealth to see if it could re­pur­pose an old chemother­a­py agent for rare dis­eases, Mer­ck KGaA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times